Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r.

Hepatology (Baltimore, Md.) - 1 Feb 2019

Fourati Slim, Rodriguez Christophe, Hézode Christophe, Soulier Alexandre, Ruiz Isaac, Poiteau Lila, Chevaliez Stéphane, Pawlotsky Jean-Michel

Abstract excerpt

Hepatitis C virus (HCV) genotype 4 is highly heterogeneous. HCV subtype 4r has been suggested to be less responsive to direct-acting antiviral (DAA) drug treatment than other genotype 4 subtypes. Among 537 DAA-treated patients who experienced a virological failure (VF) in France between 2015 and 2018, 121 (22.5%) were infected with genotype 4 and 27 of them (22.3%) with subtype 4r; subtype 4r was thus...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antiviral Agents

Share to Genome, Viral

Share to Genotype

Share to Hepacivirus

Share to Hepatitis C

Share to Treatment Failure

Source

Identifiers

PMID: 30125371
DOI: 10.1002/hep.30225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequent Antiviral Treatment Failures in Patients Infected With Hepatitis C Virus Genotype 4, Subtype 4r.PMID 30125371Read ↗

Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection.Semantic proximity Read ↗

Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome.Semantic proximity Read ↗

Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.Semantic proximity Read ↗

Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure.Semantic proximity Read ↗

Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents.Semantic proximity Read ↗

Prevalence of resistance-associated substitutions to NS3, NS5A and NS5B inhibitors at DAA-failure in hepatitis C virus in Italy from 2015 to 2019.Semantic proximity Read ↗

Virological characterization of treatment failures and retreatment outcomes in patients infected with "unusual" HCV genotype 1 subtypes.Semantic proximity Read ↗

Drug Resistance Profile and Clinical Features for Hepatitis C Patients Experiencing DAA Failure in Taiwan.Semantic proximity Read ↗

Hepatitis C genotype 4: A report on resistance-associated substitutions in NS3, NS5A, and NS5B genes.Semantic proximity Read ↗

Emergence of HCV resistance-associated variants in patients failing sofosbuvir-based regimens: an observational cohort.Semantic proximity Read ↗

Resistance Associated Mutations in HCV Patients Failing DAA Treatment.Semantic proximity Read ↗

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.